Gianfranco Lopopolo

Dr. Gianfranco Lopopolo

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Modesto de CandiaModesto de Candia
Modesto de Candia
FFFilomena Fiorella
Filomena Fiorella
GLGianfranco Lopopolo
Gianfranco Lopopolo
ACAndrea Carotti
Andrea Carotti
MRMaria Rosaria Romano
Maria Rosaria Romano
Cosimo D. AltomareCosimo D. Altomare
Cosimo D. Altomare

10 September 2009 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
Modesto de CandiaModesto de Candia
Modesto de Candia
GLGianfranco Lopopolo
Gianfranco Lopopolo
CACosimo Altomare
Cosimo Altomare
(2009). Novel factor Xa inhibitors: a patent review. Expert Opinion on Therapeutic Patents: Vol. 19, No. 11, pp. 1535-1580. doi: 10.1517/13543770903270532

1 February 2011 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
GLGianfranco Lopopolo
Gianfranco Lopopolo
FFFilomena Fiorella
Filomena Fiorella
Modesto de CandiaModesto de Candia
Modesto de Candia
Orazio NicolottiOrazio Nicolotti
Orazio Nicolotti
SMSophie Martel
Sophie Martel
CACosimo Altomare
Cosimo Altomare

20 March 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
FSFrancesco Samarelli
Francesco Samarelli
RPRosa Purgatorio
Rosa Purgatorio
GLGianfranco Lopopolo
Gianfranco Lopopolo
CDCaterina Deruvo
Caterina Deruvo
MCMarco Catto
Marco Catto
CACosimo D. Altomare
Cosimo D. Altomare
Due to the putative role of butyrylcholinesterase (BChE) in regulation of acetylcholine levels and functions in the late stages of the Alzheimer's disease (AD), the potential of selective inhibitors (BChEIs) has been envisaged as an alternative to administration of acetylcholinesterase inhibitors (AChEIs). Starting from our recent findings, herein the synthesis and in vitro evaluation of cholinesterase (ChE) inhibition of a novel series of some twenty 3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one derivatives, bearing at the indole nitrogen diverse alkyl-bridged 4-arylalkylpiperazin-1-yl chains, are reported. The length of the spacers, as well as the type of arylalkyl group affected the enzyme inhibition potency and BChE/AChE selectivity. Two compounds, namely 14c (IC50 = 163 nM) and 14d (IC50 = 65 nM), bearing at the nitrogen atom in position 6 a n-pentyl- or n-heptyl-bridged 4-phenethylpiperazin-1-yl chains, respectively, proved to be highly potent mixed-type inhibitors of both equine and human BChE isoforms, showing more than two order magnitude of selectivity over AChE. The study of binding kinetics through surface plasmon resonance (SPR) highlighted differences in their BChE residence times (8 and 47 s for 14c and 14d, respectively). Moreover, 14c and 14d proved to hit other mechanisms known to trigger neurodegeneration underlying AD and other CNS disorders. Unlike 14c, compound 14d proved also capable of inhibiting by more than 60% the in vitro self-induced aggregation of neurotoxic amyloid-β (Aβ) peptide at 100 μM concentration. On the other hand, 14c was slightly better than 14d in counteracting, at 1 and 10 μM concentration, glutamate excitotoxicity, due to over-excitation of NMDA receptors, and hydrogen peroxide-induced oxidative stress assessed in neuroblastoma cell line SH-SY5Y. This paper is dedicated to Prof. Marcello Ferappi, former dean of the Faculty of Pharmacy of the University of Bari, in the occasion of his 90th birthday.


2 July 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Rosa PurgatorioRosa Purgatorio
Rosa Purgatorio
Nicola GambacortaNicola Gambacorta
Nicola Gambacorta
Francesco SamarelliFrancesco Samarelli
Francesco Samarelli
GLGianfranco Lopopolo
Gianfranco Lopopolo
Modesto de CandiaModesto de Candia
Modesto de Candia
Cosimo D. AltomareCosimo D. Altomare
Cosimo D. Altomare
The rational discovery of new peptidomimetic inhibitors of the coagulation factor Xa (fXa) could help set more effective therapeutic options (to prevent atrial fibrillation). In this respect, we explored the conformational impact on the enzyme inhibition potency of the malonamide bridge, compared to the glycinamide one, as a linker connecting the P1 benzamidine anchoring moiety to the P4 aryl group of novel selective fXa inhibitors. We carried out structure–activity relationship (SAR) studies aimed at investigating para- or meta-benzamidine as the P1 basic group as well as diversely decorated aryl moieties as P4 fragments. To this end, twenty-three malonamide derivatives were synthesized and tested as inhibitors of fXa and thrombin (thr); the molecular determinants behind potency and selectivity were also studied by employing molecular docking. The malonamide linker, compared to the glycinamide one, does significantly increase anti-fXa potency and selectivity. The meta-benzamidine (P1) derivatives bearing 2′,4′-difluoro-biphenyl as the P4 moiety proved to be highly potent reversible fXa-selective inhibitors, achieving inhibition constants (Ki) in the low nanomolar range. The most active compounds were also tested against cholinesterase (ChE) isoforms (acetyl- or butyrylcholinesterase, AChE, and BChE), and some of them returned single-digit micromolar inhibition potency against AChE and/or BChE, both being drug targets for symptomatic treatment of mild-to-moderate Alzheimer’s disease. Compounds 19h and 22b were selected as selective fXa inhibitors with potential as multimodal neuroprotective agents.